About us
« Ensuring Access, Ensuring Patient Health,
Your Gateway to the French Market »
- 2017: Foundations in Consulting
- 2021: Expanding Expertise with AMARYLYS
- 2025: Establishment of Atessia Vigilances
- 2025: The Establishment
of Aphilæ Pharma - Aphilæ Pharma Today
The roots of Aphilæ Pharma trace back to the establishment of Atessia, a consulting firm specializing in pharmaceutical and regulatory affairs. Atessia earned a reputation for its expert guidance on regulatory affairs and compliance within the pharmaceutical industry. This foundation provided valuable insights into the complexities of the pharmaceutical sector and established high standards for regulatory excellence.
The next milestone was the creation of Amarylys, an outsourcing talent company that focused on supplying highly skilled professionals to the pharmaceutical sector. This expansion emphasized the importance of having specialized expertise to navigate the regulatory landscape and support the industry’s evolving needs.
Aphilæ Pharma was established to address the specific needs of pharmaceutical companies looking to enter the French market. As a GMP/GDP compliant structure, APHILAE PHARMA offers organization, resources, and expertise for Early Access Programs (EAPs), Compassionate Access (AAC), and Licensed (MA) products. The company quickly earned the French pharmaceutical Exploitant status, recognized as a Contract Pharmaceutical Commercial Organization (CPCO).
Today, Aphilæ Pharma operates as a local subsidiary for small, mid-size and large pharmaceutical companies, providing comprehensive support for the launch, storage, distribution, sales, and market access of medicinal products in France. Our focus on patient safety, regulatory compliance, and innovation ensures that we facilitate the seamless entry of pharmaceutical products into the French market.
Launched a dedicated entity specializing in pharmacovigilance, materiovigilance, and medical information, ensuring full post-marketing surveillance and patient safety for medicinal products and medical devices.
At Aphilæ Pharma, our mission is to facilitate the seamless entry of innovative pharmaceutical products into the French market, ensuring they meet all regulatory requirements while prioritizing patient safety and health. We strive to be the trusted partner for global pharmaceutical companies by providing expert guidance, efficient logistics, and comprehensive regulatory support.
Our vocation is to cover as many medical needs as possible: from rare diseases to the most common ones (cardiovascular…), from the most mature products to the most innovative products (biotechnology), ranging from generics to princeps. Our strong expertise allows us a broad medical reach.
Our approach is above all focused on the safety and health of patients in a quality approach and in compliance with ethics and regulations.
Patients First
At Aphilæ Pharma, we place patients at the center of everything we do. This commitment ensures that our actions and decisions prioritize patient needs, safety, and quality of life by providing rapid and effective access to medical treatments.
Partnership
We value the creation of strong partnerships with pharmaceutical companies, regulatory authorities, and healthcare professionals. These collaborations allow us to pool resources and expertise to achieve common goals and succeed together.
Professionalism
We maintain high standards of conduct and adherence to regulatory norms, ensuring that all activities are carried out with precision and in full compliance with French regulatory standards. Professionalism at Aphilæ Pharma means exercising diligence, accuracy, and integrity in every step of the process, from the facilitation of market entry to the ongoing monitoring of medicinal products.
Probity
We uphold the highest standards of integrity and honesty in all our activities. Probity means adhering to regulatory standards and Good Distribution Practices (GDP), ensuring transparency and accountability in all our operations